Sign in or create an account to add this stock to your watchlist.
About Sucampo Pharmaceuticals (NASDAQ:SCMP)
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).
Industry, Sector and Symbol
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:SCMP
CUSIP86490910
Phone+1-301-9613400
Debt
Debt-to-Equity Ratio7.37
Current Ratio5.11
Quick Ratio4.46
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E Ratio16.07
P/E Growth5.06
Sales & Book Value
Annual Sales$230.06 million
Price / Sales3.69
Cash Flow$2.4096 per share
Price / Cash7.47
Book Value$3.60 per share
Price / Book5.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$18.48 million
Net Margins16.92%
Return on Equity126.04%
Return on Assets11.04%
Miscellaneous
Employees139
Outstanding Shares47,170,000
Sucampo Pharmaceuticals (NASDAQ:SCMP) Frequently Asked Questions
What is Sucampo Pharmaceuticals' stock symbol?
Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."
How were Sucampo Pharmaceuticals' earnings last quarter?
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) announced its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.25 by $0.02. The biopharmaceutical company earned $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. Sucampo Pharmaceuticals had a net margin of 16.92% and a return on equity of 126.04%. The company's revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.30 earnings per share. View Sucampo Pharmaceuticals' Earnings History.
What price target have analysts set for SCMP?
8 brokers have issued 12-month price objectives for Sucampo Pharmaceuticals' stock. Their forecasts range from $15.00 to $43.00. On average, they expect Sucampo Pharmaceuticals' share price to reach $22.8750 in the next year. View Analyst Ratings for Sucampo Pharmaceuticals.
What are Wall Street analysts saying about Sucampo Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Sucampo’s pending acquisition by Mallinckrodt for $1.2 billion have raised investor concerns that the latter may be underpaying for the company. A sNDA for label expansion of Amitizia in pediatric functional constipation is under review. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. Moreover, Sucampo discontinued Amitzia’s sprinkle formulation development as it did not meet bioequivalence with capsule formulation. Shares of the company have outperformed the industry. Estimates have remained stable ahead of the Q4 earnings results. The company has a mixed record of earnings surprises in recent quarters." (2/9/2018)
- 2. Maxim Group analysts commented, "Sucampo’s stock has risen sharply in the past few weeks (from ~$10 to $16+) on no new fundamental news. However, a Bloomberg story has been circulating that the company may be entertaining suitors. We have no specific knowledge to confirm this, but do see an undervalued company that is generating free cash flow and has a strong (orphan) pipeline. Our last note (from 11/21) reviewed the R&D Day which focused on two key pipeline products, VTS-270 (Neeman Pick Disease) and CPP-1X/sulindac (Familial Adenomatous Polyposis )." (12/7/2017)
Who are Sucampo Pharmaceuticals' key executives?
Sucampo Pharmaceuticals' management team includes the folowing people:
- Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer (Age 47)
- Peter P. Pfreundschuh CPA, Chief Financial Officer (Age 48)
- Max Donley, Executive Vice President of Global Human Resources, Information Technology and Strategy (Age 48)
- Matthias Alder, Executive Vice President (Age 52)
- Peter A. Kiener Ph.D., Chief Scientific Officer (Age 64)
- Alex Driggs, General Counsel, Corporate Secretary (Age 41)
- Peter Lichtlen M.D., Ph.D., Chief Medical Officer (Age 47)
- John H. Johnson, Lead Independent Director (Age 58)
- Paul R. Edick, Director (Age 62)
- Daniel P. Getman Ph.D., Director (Age 59)
Has Sucampo Pharmaceuticals been receiving favorable news coverage?
Media coverage about SCMP stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sucampo Pharmaceuticals earned a media sentiment score of 0.14 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.41 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Sucampo Pharmaceuticals?
Shares of SCMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sucampo Pharmaceuticals' stock price today?
One share of SCMP stock can currently be purchased for approximately $18.00.
How big of a company is Sucampo Pharmaceuticals?
Sucampo Pharmaceuticals has a market capitalization of $839.46 million and generates $230.06 million in revenue each year. Sucampo Pharmaceuticals employs 139 workers across the globe.
How can I contact Sucampo Pharmaceuticals?
Sucampo Pharmaceuticals' mailing address is 805 King Farm Blvd Ste 550, ROCKVILLE, MD 20850-6162, United States. The biopharmaceutical company can be reached via phone at +1-301-9613400 or via email at [email protected]
MarketBeat Community Rating for Sucampo Pharmaceuticals (SCMP)
MarketBeat's community ratings are surveys of what our community members think about Sucampo Pharmaceuticals and other stocks. Vote "Outperform" if you believe SCMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sucampo Pharmaceuticals (NASDAQ:SCMP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Sucampo Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.8750, suggesting that the stock has a possible upside of 27.08%. The high price target for SCMP is $43.00 and the low price target for SCMP is $15.00. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.25 | 2.22 | 2.30 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.8750 | $21.5556 | $20.90 | $16.8750 |
| Price Target Upside: | 27.08% upside | 20.29% upside | 16.63% upside | 63.83% upside |
Sucampo Pharmaceuticals (NASDAQ:SCMP) Consensus Price Target History
Sucampo Pharmaceuticals (NASDAQ:SCMP) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Sucampo Pharmaceuticals (NASDAQ:SCMP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Sucampo Pharmaceuticals (NASDAQ SCMP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.13%
Institutional Ownership Percentage: 67.09%
Sucampo Pharmaceuticals (NASDAQ SCMP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/7/2017 | Peter A Kiener | Insider | Sell | 50,000 | $16.50 | $825,000.00 | 52,023 |  |
| 9/11/2017 | Sachiko Kuno | Major Shareholder | Sell | 1,000,000 | $12.00 | $12,000,000.00 | | |
| 9/6/2017 | Jason Patrick Meyenburg | Insider | Buy | 4,000 | $12.13 | $48,520.00 | 30,228 | |
| 8/4/2017 | Jones W Bryan | Insider | Buy | 4,700 | $10.60 | $49,820.00 | 4,700 | |
| 11/29/2016 | Daniel P Getman | Director | Sell | 20,000 | $16.86 | $337,200.00 | 16,201 | |
| 11/29/2016 | Peter Greenleaf | CEO | Sell | 200,000 | $16.84 | $3,368,000.00 | 120,054 | |
| 11/28/2016 | Matthias Alder | EVP | Sell | 150,000 | $16.00 | $2,400,000.00 | 29,449 | |
| 11/15/2016 | Andrew P Smith | CFO | Sell | 1,766 | $15.58 | $27,514.28 | 348 | |
| 8/28/2015 | Daniel P. Getman | Director | Sell | 30,000 | $28.14 | $844,200.00 | | |
| 7/20/2015 | Thomas J Knapp | Insider | Sell | 64,528 | $23.43 | $1,511,891.04 | | |
| 3/12/2015 | William Ashton | Director | Sell | 55,762 | $17.55 | $978,623.10 | | |
| 3/11/2015 | Anthony C Celeste | Director | Sell | 65,966 | $17.34 | $1,143,850.44 | | |
| 12/16/2014 | Cary J Claiborne | CFO | Sell | 50,000 | $12.91 | $645,500.00 | | |
| 12/15/2014 | Cary J Claiborne | CFO | Sell | 7,100 | $12.89 | $91,519.00 | | |
| 8/7/2014 | Sachiko Kuno | Major Shareholder | Sell | 181,727 | $6.28 | $1,141,245.56 | | |
| 8/4/2014 | Ryuji Ueno | Major Shareholder | Sell | 140,873 | $6.02 | $848,055.46 | | |
| 7/31/2014 | S&R Technology Holdings, Llc | Major Shareholder | Sell | 100 | $6.25 | $625.00 | | |
| 7/30/2014 | S&R Technology Holdings, Llc | Major Shareholder | Sell | 300 | $6.25 | $1,875.00 | | |
| 7/25/2014 | Ryuji Ueno | Major Shareholder | Sell | 16,155 | $6.26 | $101,130.30 | | |
| 7/23/2014 | Ryuji Ueno | Major Shareholder | Sell | 5,845 | $6.29 | $36,765.05 | | |
| 7/22/2014 | S&R Technology Holdings, Llc | Major Shareholder | Sell | 2,500 | $6.25 | $15,625.00 | | |
| 7/21/2014 | S&R Technology Holdings, Llc | Major Shareholder | Sell | 100 | $6.25 | $625.00 | | |
| 7/18/2014 | S&R Technology Holdings, Llc | Major Shareholder | Sell | 15,000 | $6.27 | $94,050.00 | | |
| 4/29/2014 | S&R Technology Holdings, Llc | major shareholder | Sell | 113,600 | $6.65 | $755,440.00 | 22,820,802 | |
| 4/25/2014 | Sachiko Kuno | major shareholder | Sell | 118,700 | $6.69 | $794,103.00 | 60,357 | |
| 3/18/2014 | Gayle Dolecek | Director | Sell | 1,200 | $8.03 | $9,636.00 | | |
| 2/27/2014 | Cary Claiborne | CFO | Sell | 2,500 | $9.00 | $22,500.00 | | |
| 1/17/2014 | Ryuji Ueno | CEO | Sell | 360,000 | $10.36 | $3,729,600.00 | 148,530 | |
| 1/7/2014 | Cary Claiborne | CFO | Sell | 2,500 | $9.00 | $22,500.00 | | |
| 10/16/2013 | Sachiko Kuno | Major Shareholder | Sell | 360,000 | $6.35 | $2,286,000.00 | | |
| 9/18/2013 | Ryuji Ueno | CEO | Sell | 38,462 | $5.69 | $218,848.78 | 148,530 | |
| 9/3/2013 | Ryuji Ueno | CEO | Sell | 38,462 | $5.59 | $215,002.58 | 148,530 | |
| 8/19/2013 | Ryuji Ueno | CEO | Sell | 38,462 | $6.04 | $232,310.48 | 148,530 | |
| 8/6/2013 | Sachiko Kuno | major shareholder | Sell | 38,462 | $6.21 | $238,849.02 | 60,357 | |
| 7/24/2013 | Ryuji Ueno | CEO | Sell | 38,462 | $6.52 | $250,772.24 | | |
| 7/9/2013 | S&R Technology Holdings, Llc | Major Shareholder | Sell | 38,462 | $6.48 | $249,233.76 | | |
| 6/24/2013 | S&R Technology Holdings, Llc | Major Shareholder | Sell | 38,462 | $6.61 | $254,233.82 | | |
| 6/10/2013 | Sachiko Kuno | Major Shareholder | Sell | 38,462 | $7.29 | $280,387.98 | | |
| 5/28/2013 | Ryuji Ueno | CEO | Sell | 38,462 | $8.79 | $338,080.98 | | |
| 5/21/2013 | Cary J Claiborne | CFO | Sell | 4,640 | $9.52 | $44,172.80 | | |
| 5/20/2013 | Stanley G Miele | SVP | Sell | 6,400 | $9.60 | $61,440.00 | | |
| 5/16/2013 | Stanley G Miele | SVP | Sell | 48,600 | $9.67 | $469,962.00 | | |
| 5/15/2013 | Timothy I Maudlin | Director | Buy | 32,870 | $9.82 | $322,783.40 | | |
| 5/13/2013 | Sachiko Kuno | Major Shareholder | Sell | 38,462 | $9.27 | $356,542.74 | | |
| 2/4/2013 | S&R Technology Holdings, Llc | Major Shareholder | Sell | 38,462 | $5.22 | $200,771.64 | | |
| 12/26/2012 | S&R Technology Holdings, Llc | Major Shareholder | Sell | 20,262 | $5.01 | $101,512.62 | | |
| 11/27/2012 | Sachiko Kuno | Major Shareholder | Sell | 12,205 | $5.00 | $61,025.00 | | |
| 11/13/2012 | Sachiko Kuno | Major Shareholder | Sell | 11,962 | $5.00 | $59,810.00 | | |
| 11/1/2012 | Sachiko Kuno | Major Shareholder | Sell | 37,595 | $5.06 | $190,230.70 | | |
(Data available from 1/1/2013 forward)
Sucampo Pharmaceuticals (NASDAQ SCMP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Sucampo Pharmaceuticals, Inc. (SCMP) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 30 at 3:34 AM |
| Sucampo Pharmaceuticals (SCMP) Downgraded by TheStreet to "D"
www.americanbankingnews.com - April 13 at 10:15 AM |
| Sucampo Pharmaceuticals, Inc. (SCMP) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 5 at 3:08 AM |
| Sucampo Pharmaceuticals' (SCMP) Buy Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - April 1 at 11:24 PM |
| Sucampo Pharmaceuticals (SCMP) Lowered to "Hold" at Maxim Group
www.americanbankingnews.com - March 31 at 2:06 PM |
| Sucampo Pharmaceuticals' (SCMP) "Neutral" Rating Reaffirmed at Mizuho
www.americanbankingnews.com - March 31 at 12:46 AM |
| Medivation (MDVN) versus Sucampo Pharmaceuticals (SCMP) Head to Head Comparison
www.americanbankingnews.com - March 28 at 3:16 PM |
 | Cerecor Appoints Peter Greenleaf as Chief Executive Officer
finance.yahoo.com - March 28 at 9:24 AM |
| Financial Review: Sucampo Pharmaceuticals (SCMP) and Kythera Biopharmaceuticals (KYTH)
www.americanbankingnews.com - March 25 at 5:17 AM |
| Sucampo Pharmaceuticals, Inc. (SCMP) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 11 at 5:33 AM |
| 150,000 Shares in Sucampo Pharmaceuticals, Inc. (SCMP) Acquired by Water Island Capital LLC
www.americanbankingnews.com - March 2 at 9:50 PM |
| Sucampo Pharmaceuticals (SCMP) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 27 at 2:34 AM |
| 58,840 Shares in Sucampo Pharmaceuticals, Inc. (SCMP) Purchased by Virtu Financial LLC
www.americanbankingnews.com - February 25 at 2:32 PM |
| Analyzing Sucampo Pharmaceuticals (SCMP) and Kura Oncology (KURA)
www.americanbankingnews.com - February 23 at 5:12 AM |
| BidaskClub Downgrades Sucampo Pharmaceuticals (SCMP) to Buy
www.americanbankingnews.com - February 18 at 1:00 PM |
| Sucampo Pharmaceuticals, Inc. (SCMP) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 14 at 3:34 AM |
| Sucampo Pharmaceuticals (SCMP) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - February 9 at 8:58 PM |
 | Quotidian Technical Highlights on Selected Drug Makers Stocks -- Novo Nordisk, Sucampo Pharma, Synergy Pharma, and Teva Pharmaceutical Industries
www.bizjournals.com - February 9 at 9:24 AM |
| ValuEngine Upgrades Sucampo Pharmaceuticals (SCMP) to "Strong-Buy"
www.americanbankingnews.com - February 4 at 2:19 PM |
| Barclays: Mallinckrodt's Sucampo Deal Overshadowed By Competitive Threats
finance.yahoo.com - February 3 at 9:14 AM |
| Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Announce Quarterly Sales of $75.59 Million
www.americanbankingnews.com - February 3 at 2:36 AM |
| $0.34 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter
www.americanbankingnews.com - February 1 at 7:22 PM |
| Sucampo Pharmaceuticals (SCMP) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - February 1 at 11:12 AM |
| Sucampo Pharmaceuticals (SCMP) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 31 at 1:12 PM |
| Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Sucampo Pharmaceuticals, Inc. In The District Of Maryland
finance.yahoo.com - January 26 at 9:27 AM |
| Sucampo Pharmaceuticals (SCMP) Rating Reiterated by Nomura
www.americanbankingnews.com - January 26 at 8:46 AM |
| SUCAMPO PHARMACEUTICALS (SCMP) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Sucampo Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty
finance.yahoo.com - January 22 at 6:03 PM |
 | Lifshitz & Miller LLP Announces Investigation of Advanced Micro Devices, Aflac Incorporated, DST Systems, Inc., Forum Merger Corporation, GoPro, Inc., Sucampo Pharmaceuticals, Inc. and ZAIS Group Holdings, Inc.
www.prnewswire.com - January 21 at 1:46 AM |
| Sucampo Pharmaceuticals, Inc. (SCMP) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 20 at 3:38 AM |
| $75.59 Million in Sales Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter
www.americanbankingnews.com - January 17 at 2:40 AM |
| Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Announce Earnings of $0.34 Per Share
www.americanbankingnews.com - January 15 at 9:14 PM |
| Aradigm's Bronchiectasis Candidate Has Negative FDA Vote
finance.yahoo.com - January 12 at 3:33 PM |
| Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?
finance.yahoo.com - January 12 at 11:23 AM |
| Sucampo Pharmaceuticals (SCMP) Cut to "Neutral" at UBS Group
www.americanbankingnews.com - January 7 at 8:37 AM |
| Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Post FY2019 Earnings of $1.79 Per Share
www.americanbankingnews.com - January 5 at 6:34 PM |
| Are Options Traders Betting on a Big Move in Sucampo (SCMP) Stock?
finance.yahoo.com - January 5 at 11:12 AM |
| Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod
finance.yahoo.com - January 5 at 11:12 AM |
| Omeros Inks Agreement With FDA for OMS721 Phase III Trial
finance.yahoo.com - January 4 at 11:17 AM |
| Wolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plc - PR Newswire (press release)
www.prnewswire.com - January 2 at 8:51 PM |
| Wolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plc
finance.yahoo.com - January 2 at 11:10 AM |
| Sucampo Pharmaceuticals (SCMP) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - January 2 at 8:48 AM |
| SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceuticals, Inc ... - PR Newswire (press release)
www.prnewswire.com - January 1 at 3:35 PM |
| Sucampo Pharmaceuticals (SCMP) Upgraded at ValuEngine
www.americanbankingnews.com - January 1 at 11:22 AM |
| SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceuticals, Inc. -- SCMP
finance.yahoo.com - January 1 at 11:07 AM |
| SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Sucampo Pharmaceuticals, Inc. - SCMP
finance.yahoo.com - December 29 at 10:51 AM |
| Sucampo Pharmaceuticals, Inc. (SCMP) Sees Large Increase in Short Interest
www.americanbankingnews.com - December 29 at 1:58 AM |
| CORRECTING and REPLACING Investor Alert: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Sucampo Pharmaceuticals, Inc. to Mallinckrodt plc is Fair to Shareholders
finance.yahoo.com - December 28 at 3:10 PM |
| Wired News - Mallinckrodt to Acquire Sucampo Pharmaceuticals
finance.yahoo.com - December 28 at 8:53 AM |
 | Mallinckrodt to Buy Sucampo Pharmaceuticals for About $840 Million
www.wsj.com - December 27 at 6:11 PM |
| Mallinckrodt International Finance SA -- Moody's places Mallinckrodt's ratings under review for downgrade following Sucampo announcement
finance.yahoo.com - December 27 at 6:11 PM |
Sucampo Pharmaceuticals (NASDAQ:SCMP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sucampo Pharmaceuticals (NASDAQ:SCMP) Income Statement, Balance Sheet and Cash Flow Statement
Sucampo Pharmaceuticals (NASDAQ SCMP) Stock Chart for Saturday, May, 26, 2018
Loading chart…
